Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 2Somatostatinoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

Octreotide 4Everolimus 4Capecitabine 3Temozolomide 2Melphalan 2Biological Therapy 2vatalanib 1temsirolimus 1romidepsin 1regorafenib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fluorouracil 1Filgrastim 1Cytokines 1Complementary Therapies 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Islet Cell × Complementary Therapies × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡